List of Excipients in Branded Drug OXYCODONE HCL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
KVK-Tech Inc	OXYCODONE HCL	oxycodone hcl	10702-801	BUTYLATED HYDROXYTOLUENE
KVK-Tech Inc	OXYCODONE HCL	oxycodone hcl	10702-801	HYDROXYPROPYL CELLULOSE
KVK-Tech Inc	OXYCODONE HCL	oxycodone hcl	10702-801	HYPROMELLOSES

Generic Drugs Containing OXYCODONE HCL

Company	Ingredient	NDC	Excipient
DIRECT RX	oxycodone hcl	61919-659	ANHYDROUS LACTOSE
DIRECT RX	oxycodone hcl	61919-659	CELLULOSE, MICROCRYSTALLINE
DIRECT RX	oxycodone hcl	61919-659	D&C YELLOW NO. 10

What are the Most Frequently-Used Excipients in OXYCODONE HCL?

# Of NDCs	Excipient
1	ANHYDROUS LACTOSE
7	CELLULOSE, MICROCRYSTALLINE
1	D&C RED NO. 30

Oxycodone HCl Excipient Strategy and Commercial Opportunities: Formulation, Abuse Deterrence and Generic Entry

Last updated: August 20, 2026

Oxycodone HCl has established demand across immediate-release tablets, extended-release tablets, oral solutions and injectable products. The largest excipient opportunities are in abuse-deterrent extended-release formulations, low-volume pediatric liquids, preservative-controlled injectables, orally disintegrating dosage forms and differentiated generic products. Commercial success depends on controlling opioid-release kinetics, limiting manipulation, meeting extractables and leachables requirements, and avoiding excipient-driven pharmacokinetic differences.

What excipient strategies are commercially relevant for oxycodone HCl?

The strongest strategy is to match excipient selection to the dosage form and regulatory pathway.

Product segment	Primary excipient objective	Commercial opportunity
Immediate-release tablets	Fast dissolution, mechanical strength, low cost	Commodity generics and differentiated swallowability
Extended-release tablets	12-hour release, dose proportionality, abuse deterrence	Higher-value complex generics and branded reformulations
Oral solutions	Solubility, taste masking, preservative control	Pediatric, geriatric and institutional use
Injectable solutions	Sterility, pH control, tonicity and container compatibility	Hospital and emergency-care supply
Orally disintegrating tablets	Rapid dispersion without altering exposure	Specialty generics and administration convenience
Abuse-deterrent products	Resistance to crushing, powder formation, extraction and rapid release	Branded lifecycle management and complex ANDAs

Oxycodone HCl is highly water soluble, which reduces the need for solubilization technology in standard oral liquids and injectables. The more difficult formulation problem is controlling release while preserving bioequivalence and limiting abuse through crushing, chewing or solvent extraction.

What excipients are used in oxycodone HCl products?

FDA-approved oxycodone products use conventional tablet excipients, controlled-release polymers, solvents, preservatives and coating systems. The exact composition varies by manufacturer and dosage form.

Immediate-release tablets

Typical excipient classes include:

• Microcrystalline cellulose or lactose as diluents
• Povidone or copovidone as binders
• Croscarmellose sodium, sodium starch glycolate or crospovidone as disintegrants
• Magnesium stearate or sodium stearyl fumarate as lubricants
• Colloidal silicon dioxide as a glidant
• Hypromellose, titanium dioxide and iron oxides in film coatings

The commercial objective is a robust, low-cost tablet with rapid and consistent dissolution. For ANDA products, excipient selection must support comparable dissolution profiles across multiple pH conditions and maintain stability through the proposed shelf life.

Extended-release tablets

Extended-release oxycodone products use matrix or coating systems that slow drug diffusion and tablet erosion. Relevant excipient classes include:

• Polyethylene oxide
• Hypromellose
• Ethylcellulose
• Methacrylate copolymers
• Hydroxypropyl cellulose
• Fatty alcohols and waxes
• Povidone and other granulation aids
• Mineral-based or polymeric coating systems

OxyContin extended-release tablets use a polymeric matrix and have been marketed with an abuse-deterrent formulation. The product labeling identifies polyethylene oxide among the formulation components and describes resistance to crushing and rapid release under specified manipulation conditions (FDA, 2023a).

Oral solutions

Oxycodone HCl oral solutions generally require:

• Purified water
• pH adjusters
• Sweeteners
• Flavoring agents
• Preservatives, where applicable
• Chelating agents or antioxidants, where justified
• Viscosity modifiers for dose-measurement control

The key technical risk is not drug solubility. It is palatability, dose accuracy, microbial control and prevention of accidental concentration errors. Lower-strength presentations can create a commercial advantage in pediatric and geriatric settings, but labeling and measuring-device design must prevent dosing mistakes.

Injectable formulations

Injectable oxycodone HCl products require a narrow formulation window for:

• pH
• Osmolality
• Sterility
• Particulate control
• Container closure integrity
• Compatibility with glass, plastic syringes and infusion systems

Common excipient functions include sodium chloride for tonicity and hydrochloric acid or sodium hydroxide for pH adjustment. Preservatives may be appropriate for multidose presentations but create additional tolerability and regulatory considerations.

How can excipients create abuse-deterrent oxycodone products?

Abuse-deterrent excipient systems use physical and chemical barriers. FDA classifies abuse-deterrent technologies by their ability to address specific manipulation routes, including physical crushing, chemical extraction and rapid drug release (FDA, 2015).

Physical barriers

High-molecular-weight polymers can create a hard matrix that resists crushing and produces larger fragments rather than a fine powder. Polyethylene oxide and high-viscosity hypromellose are relevant candidates.

Design variables include:

• Polymer molecular weight
• Polymer loading
• Compression force
• Granule porosity
• Tablet hardness
• Water uptake
• Matrix erosion rate

The formulation must prevent dose dumping without creating unacceptable food effects, delayed onset or incomplete drug release.

Gelling systems

Hydrophilic polymers can form viscous gels when exposed to water or aqueous solvents. The gel can reduce syringeability and limit extraction of oxycodone HCl.

Commercially relevant materials include:

• Polyethylene oxide
• Hypromellose
• Hydroxypropyl cellulose
• Carbomers
• Crosslinked acrylic polymers

A gelling system must be evaluated against real-world manipulation conditions. Excessive gel formation can impair oral performance, create manufacturing problems and reduce patient acceptability.

Chemical and extraction barriers

Ion-exchange resins, functionalized polymers and sequestration agents can reduce oxycodone availability after manipulation. These systems are technically more complex because they must preserve intended oral bioavailability while limiting extraction in non-oral solvents.

Potential development issues include:

• Drug loading uniformity
• Resin particle-size control
• Effect on release across gastrointestinal pH
• Interaction with co-administered medicines
• Long-term stability
• Demonstration of no clinically meaningful exposure change

The commercial value of these approaches is highest when the technology supports FDA abuse-deterrent labeling rather than merely increasing tablet hardness.

What formulation patents protect oxycodone HCl products?

Patent protection for oxycodone HCl depends on the specific product, dosage form and jurisdiction. The original immediate-release oxycodone molecule is long off patent, so commercial protection typically comes from formulation, abuse-deterrence, manufacturing and method-of-use claims.

Patent categories

Patent category	Typical claim scope	Business impact
Controlled-release matrix	Polymer composition, drug loading and release profile	Can delay complex-generic entry
Abuse-deterrent formulation	Crush resistance, gel formation and extraction resistance	Supports differentiated branded products
Manufacturing process	Granulation, compression, coating and curing	May create process barriers
Dosage regimen	Twelve-hour dosing or treatment-specific use	Usually narrower enforcement value
Combination product	Oxycodone with naloxone or another antagonist	Creates separate product estate
Packaging and delivery	Dosing systems and tamper-resistant packaging	Often complementary rather than decisive

OxyContin-related patent protection has included controlled-release and abuse-deterrent technologies. The exact status of each listed patent must be checked in the current FDA Orange Book and the relevant national patent register because expiry dates can vary with patent-term adjustment, pediatric extensions, terminal disclaimers and regulatory exclusivity (FDA, 2024a).

Patent-strength assessment

An oxycodone excipient patent estate is stronger when it has:

1. Claims covering the functional result, not only a named polymer.
2. Multiple polymer and loading ranges.
3. Independent claims covering crushing, extraction and dissolution behavior.
4. Manufacturing claims that are difficult to design around.
5. Data linking excipient structure to pharmacokinetic and abuse-deterrence performance.
6. Continuation or divisional applications covering alternative matrices.
7. Claims that survive reasonable substitutions of hypromellose, polyethylene oxide, ethylcellulose or acrylic polymers.

A narrow claim to one excipient at one concentration is easier to avoid. A claim covering a release profile combined with abuse-deterrent performance is more difficult for competitors to design around but may be harder to enforce.

When does oxycodone HCl lose exclusivity?

Immediate-release oxycodone HCl has generic competition and is commercially mature. The relevant exclusivity question concerns the specific product, strength, dosage form and formulation.

Exclusivity type	Relevance to oxycodone HCl
Active-ingredient patent	Generally no longer commercially controlling for standard oxycodone HCl
Immediate-release formulation patent	Usually limited or expired for legacy products
Extended-release formulation patent	May remain relevant for specific branded products
Abuse-deterrent formulation patent	Potentially important for branded lifecycle products
New drug exclusivity	Applies to qualifying new formulations, not the old molecule generally
Orphan exclusivity	Usually not central to ordinary oxycodone products
Pediatric exclusivity	Can add six months to qualifying listed patents or exclusivity

Generic companies can enter standard immediate-release products where no enforceable formulation or regulatory barrier remains. Extended-release entry is more dependent on Orange Book-listed patents, Paragraph IV litigation and the ability to demonstrate bioequivalence to a complex reference product.

How many patents cover oxycodone HCl products?

There is no single meaningful patent count for oxycodone HCl as a molecule. Counts differ depending on whether the analysis includes:

• Expired composition-of-matter patents
• Active formulation patents
• Orange Book-listed patents
• Pending applications
• Continuations
• Foreign family members
• Manufacturing patents
• Method-of-use claims
• Packaging patents

For commercial diligence, the relevant count is the number of unexpired, enforceable patent families that read on the target product and can block approval or launch. A raw count of global applications can materially overstate protection.

What is the Orange Book status of oxycodone HCl?

The FDA Orange Book identifies approved drug products, reference listed drugs, therapeutic equivalents and, where applicable, patent and exclusivity information. Standard oxycodone HCl immediate-release products are generally associated with established generic competition. Extended-release products require a product-specific review of:

• Reference listed drug designation
• Listed patents
• Patent-use codes
• Pediatric exclusivity
• Approved strengths
• Therapeutic-equivalence codes
• Current marketing status

The Orange Book does not replace a freedom-to-operate analysis. It does not capture every potentially relevant manufacturing patent, foreign patent, trade secret or non-listed formulation claim (FDA, 2024a).

Which companies are challenging oxycodone HCl products?

Competition exists among generic manufacturers, specialty pharmaceutical companies and branded opioid developers. Generic suppliers commonly compete on:

• Immediate-release tablet strengths
• Extended-release tablets
• Oral solutions
• Injectable presentations
• Hospital contracts
• Supply reliability
• Controlled-substance distribution compliance

Paragraph IV challenges become commercially relevant when a generic applicant asserts that an Orange Book-listed patent is invalid, unenforceable or not infringed. For extended-release oxycodone, litigation risk is higher because the reference product may involve complex release behavior and abuse-deterrent performance.

A generic applicant can also pursue a Paragraph III certification, wait for patent expiry, or submit a product that avoids a listed patent. The strategy affects launch timing, litigation cost and the probability of a first-filer advantage.

What generic entry risks exist for oxycodone HCl?

Immediate-release products

The main risks are price erosion, supply-chain competition and controlled-substance compliance. Excipients have limited ability to defend margins unless they support a meaningful advantage such as:

• Lower tablet weight
• Reduced friability
• Better swallowability
• Less problematic inactive ingredients
• Improved stability
• Better dose uniformity
• Lower manufacturing cost

Extended-release products

Risks are more substantial:

• Failure to match the reference pharmacokinetic profile
• Food-effect differences
• Dose dumping under alcohol or high-fat conditions
• Insufficient abuse-deterrence data
• Polymer variability
• Scale-up failures
• Patent litigation
• Restricted labeling claims

FDA guidance recognizes that abuse-deterrent formulations reduce, but do not eliminate, abuse risk. The agency evaluates the technology by category and does not treat an abuse-deterrent label as proof that abuse is impossible (FDA, 2015).

What formulations are protected by oxycodone HCl excipient patents?

The most defensible formulations usually combine composition claims with performance limitations.

High-value formulation targets

1. A polyethylene oxide or hypromellose matrix with defined release at multiple dissolution conditions.
2. A tablet that remains physically resistant after mechanical manipulation.
3. A formulation that forms a high-viscosity gel in water or alcohol.
4. A system that limits oxycodone extraction while preserving oral bioavailability.
5. A multiparticulate product with controlled-release beads or pellets.
6. A low-dose liquid with improved taste masking and dose-measurement accuracy.
7. A tamper-resistant product with a manufacturing process that reduces scale-up variability.

The strongest opportunity is a platform patent that covers alternative excipients by function. For example, a claim directed to a defined gel strength or extraction profile may provide broader protection than a claim limited to one grade of polyethylene oxide.

How does oxycodone HCl compare with other opioid formulation opportunities?

Attribute	Oxycodone HCl	Hydromorphone HCl	Morphine sulfate	Buprenorphine
Oral solubility challenge	Low	Moderate	Moderate	Higher formulation complexity
Extended-release opportunity	High	Moderate	High	High for transmucosal systems
Abuse-deterrent value	High	Moderate	High	High, but different risk profile
Generic competition	Strong	Moderate	Strong	Increasing
Excipient differentiation	Polymer matrices and liquids	Dose uniformity and controlled release	Matrix and multiparticulate systems	Mucoadhesive and permeation systems
Regulatory complexity	High for controlled release	High	High	High, including diversion controls

Oxycodone HCl is attractive for excipient innovation because it has established demand, multiple dosage forms and a clear need for controlled-release and abuse-deterrent technologies. The same factors increase regulatory and litigation risk.

What licensing deals and commercial models are available?

Excipient and formulation companies can monetize oxycodone technology through several structures:

• Exclusive regional licensing of an abuse-deterrent platform
• Co-development with a generic manufacturer
• Formulation technology transfer with milestone payments
• Royalty-bearing supply of a proprietary excipient
• Contract development and manufacturing
• Acquisition of a formulation patent family
• Licensing of a ready-to-file ANDA or 505(b)(2) product

A proprietary excipient can command stronger economics when it is difficult to substitute and has a regulatory history in controlled-release products. A standard polymer such as hypromellose or polyethylene oxide generally provides limited pricing power unless the supplier controls a specialized grade, particle-size distribution or processing technology.

Publicly announced opioid licensing transactions should be reviewed separately from excipient rights. A license to a drug product may not include rights to the excipient supplier's manufacturing process, analytical methods or foreign patent family.

What FDA regulatory status applies to new oxycodone HCl excipient products?

ANDA pathway

An ANDA is appropriate where the proposed product can demonstrate pharmaceutical equivalence and bioequivalence to a reference listed drug. Complex extended-release or abuse-deterrent products may require extensive in vitro, pharmacokinetic and human abuse-potential studies.

505(b)(2) pathway

A 505(b)(2) application may be appropriate for a materially different dosage form, strength, route, excipient system or delivery profile where the applicant relies partly on FDA findings for an approved oxycodone product. This route can support:

• New oral-liquid concentrations
• New delivery devices
• Novel multiparticulate systems
• Modified administration options
• New abuse-deterrent technologies

The 505(b)(2) pathway does not eliminate patent, exclusivity or controlled-substance requirements.

Excipient regulatory barriers

New or novel excipients create added development risk. FDA may require information on:

• Toxicology
• Prior human exposure
• Genotoxicity
• Local tolerability
• Impurity profile
• Residual solvents
• Elemental impurities
• Extractables and leachables
• Drug-excipient compatibility

Using compendial or previously approved excipients reduces regulatory friction but may narrow differentiation.

What manufacturing and intellectual-property barriers matter most?

Manufacturing is a central barrier for extended-release oxycodone products. Important process controls include:

• Polymer dispersion
• Granulation endpoint
• Moisture content
• Compression force
• Tablet hardness
• Coating weight gain
• Curing conditions
• Blend uniformity
• Dissolution across pH conditions
• Resistance to mechanical manipulation

A formulation that performs well at laboratory scale may fail after commercial scale-up because polymer distribution, tablet density and coating variability alter release kinetics.

Trade secrets can protect process parameters that are difficult to infer from the finished product. These protections can complement patents but do not block an independently developed process. Controlled-substance manufacturing also requires DEA registration, inventory controls, quotas, security systems and recordkeeping under the Controlled Substances Act (DEA, 2024).

What is the commercial outlook for oxycodone HCl excipients?

The best opportunities are not in another low-cost immediate-release tablet. They are in products that combine a clear clinical or operational advantage with a defensible formulation platform.

Priority opportunities

1. Abuse-deterrent extended-release tablets with broad polymer claims.
2. Lower-concentration oral solutions with improved dosing safety.
3. Preservative-free or low-preservative sterile presentations.
4. Multiparticulate extended-release products with reduced dose-dumping risk.
5. Excipient grades optimized for controlled-substance compression and scale-up.
6. Formulations that reduce tablet size while preserving the oxycodone release profile.
7. Products designed for institutional administration with tamper-resistant packaging and dosing controls.

Revenue exposure remains concentrated in branded and complex extended-release products rather than standard immediate-release oxycodone. Generic entry can rapidly compress prices in simple dosage forms. Differentiated excipients must therefore support regulatory exclusivity, measurable manufacturing performance or a clear procurement advantage.

Key Takeaways

• Oxycodone HCl is a mature active ingredient with continuing opportunity in complex dosage forms.
• The highest-value excipient strategy is an abuse-deterrent extended-release matrix.
• Polyethylene oxide, hypromellose, ethylcellulose and acrylic polymers are central formulation candidates.
• Immediate-release products are price-sensitive and difficult to defend through conventional excipient changes alone.
• Oral solutions offer opportunities in pediatric, geriatric and institutional markets, but taste, dosing and microbial control are critical.
• Extended-release products face the greatest bioequivalence, patent, manufacturing and FDA risks.
• Orange Book analysis must be product-specific and should be combined with a global freedom-to-operate review.
• Novel excipients can improve differentiation but may increase toxicology and regulatory requirements.
• A broad patent estate should cover functional performance, alternative polymers, manufacturing conditions and extraction resistance.
• Generic launch timing depends on Paragraph IV certifications, patent expiry, litigation settlements and the ability to reproduce the reference release profile.

FAQs About Oxycodone HCl Excipient Strategy

Can polyethylene oxide be used in a generic oxycodone HCl extended-release tablet?

Yes. Polyethylene oxide can be used where the formulation meets FDA quality, bioequivalence, dissolution and stability requirements. Patent claims covering a particular polymer grade, concentration or performance profile must be assessed separately.

Is an abuse-deterrent oxycodone HCl formulation automatically protected from generic competition?

No. Abuse-deterrent labeling does not prevent generic approval. A generic applicant may challenge patents, design around claims or develop a product that satisfies applicable FDA requirements without using the same excipient system.

Are novel excipients commercially attractive for oxycodone HCl?

They can be attractive where the excipient creates a measurable release, extraction or manufacturing advantage. The regulatory burden is higher because FDA may require additional safety and compatibility information.

Can an oxycodone HCl oral solution support a 505(b)(2) application?

Potentially. A materially different concentration, delivery system, taste-masking approach or administration profile may support a 505(b)(2) strategy, subject to FDA requirements and applicable patent or exclusivity rights.

Which oxycodone HCl product has the greatest excipient value?

Abuse-deterrent extended-release tablets generally offer the greatest excipient value because they combine formulation complexity, higher technical barriers and potential differentiation from commodity immediate-release products.

References

1. Drug Enforcement Administration. (2024). Controlled substances security requirements and registrant obligations. U.S. Department of Justice.

2. U.S. Food and Drug Administration. (2015). Guidance for industry: Abuse-deterrent opioids: Evaluation and labeling. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2023a). OxyContin (oxycodone hydrochloride) extended-release tablets prescribing information. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

5. U.S. Food and Drug Administration. (2024b). Guidance for industry: Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA. U.S. Department of Health and Human Services.